Literature DB >> 10920030

Sodium dodecyl sulfate-resistant complexes of Alzheimer's amyloid beta-peptide with the N-terminal, receptor binding domain of apolipoprotein E.

A A Golabek1, E Kida, M Walus, C Perez, T Wisniewski, C Soto.   

Abstract

Immunocytochemical, biochemical, and molecular genetic studies indicate that apolipoprotein E (apoE) plays an important role in the process of amyloidogenesis-beta. However, there is still no clear translation of these data into the pathogenesis of amyloidosis-beta. Previous studies demonstrated sodium dodecyl sulfate (SDS)-resistant binding of apoE to the main component of Alzheimer's amyloid-A beta and modulation of A beta aggregation by apoE in vitro. To more closely characterize apoE-A beta interactions, we have studied the binding of thrombolytic fragments of apoE3 to A beta in vitro by using SDS-polyacrylamide gel electrophoresis and intrinsic fluorescence quenching. Here we demonstrate that SDS-resistant binding of A beta is mediated by the receptor-binding, N-terminal domain of apoE3. Under native conditions, both the N- and C-terminal domains of apoE3 bind A beta; however, the former does so with higher affinity. We propose that the modulation of A beta binding to the N-terminal domain of apoE is a potential therapeutic target for the treatment of amyloidosis-beta.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10920030      PMCID: PMC1300996          DOI: 10.1016/S0006-3495(00)76354-5

Source DB:  PubMed          Journal:  Biophys J        ISSN: 0006-3495            Impact factor:   4.033


  59 in total

1.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families.

Authors:  E H Corder; A M Saunders; W J Strittmatter; D E Schmechel; P C Gaskell; G W Small; A D Roses; J L Haines; M A Pericak-Vance
Journal:  Science       Date:  1993-08-13       Impact factor: 47.728

2.  Expression of human apolipoprotein E reduces amyloid-beta deposition in a mouse model of Alzheimer's disease.

Authors:  D M Holtzman; K R Bales; S Wu; P Bhat; M Parsadanian; A M Fagan; L K Chang; Y Sun; S M Paul
Journal:  J Clin Invest       Date:  1999-03       Impact factor: 14.808

3.  Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid.

Authors:  T Wisniewski; B Frangione
Journal:  Neurosci Lett       Date:  1992-02-03       Impact factor: 3.046

4.  Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease.

Authors:  Y Namba; M Tomonaga; H Kawasaki; E Otomo; K Ikeda
Journal:  Brain Res       Date:  1991-02-08       Impact factor: 3.252

5.  Apolipoprotein E: binding to soluble Alzheimer's beta-amyloid.

Authors:  T Wisniewski; A Golabek; E Matsubara; J Ghiso; B Frangione
Journal:  Biochem Biophys Res Commun       Date:  1993-04-30       Impact factor: 3.575

6.  Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease.

Authors:  A M Saunders; W J Strittmatter; D Schmechel; P H George-Hyslop; M A Pericak-Vance; S H Joo; B L Rosi; J F Gusella; D R Crapper-MacLachlan; M J Alberts
Journal:  Neurology       Date:  1993-08       Impact factor: 9.910

7.  Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids.

Authors:  P Seubert; C Vigo-Pelfrey; F Esch; M Lee; H Dovey; D Davis; S Sinha; M Schlossmacher; J Whaley; C Swindlehurst
Journal:  Nature       Date:  1992-09-24       Impact factor: 49.962

8.  The apolipoprotein E polymorphism: a comparison of allele frequencies and effects in nine populations.

Authors:  D M Hallman; E Boerwinkle; N Saha; C Sandholzer; H J Menzel; A Csázár; G Utermann
Journal:  Am J Hum Genet       Date:  1991-08       Impact factor: 11.025

9.  Production of the Alzheimer amyloid beta protein by normal proteolytic processing.

Authors:  M Shoji; T E Golde; J Ghiso; T T Cheung; S Estus; L M Shaffer; X D Cai; D M McKay; R Tintner; B Frangione
Journal:  Science       Date:  1992-10-02       Impact factor: 47.728

10.  Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease.

Authors:  W J Strittmatter; A M Saunders; D Schmechel; M Pericak-Vance; J Enghild; G S Salvesen; A D Roses
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-01       Impact factor: 11.205

View more
  5 in total

1.  Sensitivity to Alternaria alternata toxin in citrus because of altered mitochondrial RNA processing.

Authors:  Kouhei Ohtani; Hiroyuki Yamamoto; Kazuya Akimitsu
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-12       Impact factor: 11.205

2.  Apolipoprotein E structural requirements for the formation of SDS-stable complexes with beta-amyloid-(1-40): the role of salt bridges.

Authors:  Nicholas M Bentley; Mary Jo Ladu; Chandrika Rajan; Godfrey S Getz; Catherine A Reardon
Journal:  Biochem J       Date:  2002-08-15       Impact factor: 3.857

3.  Insertion of the amyloid precursor protein into lipid monolayers: effects of cholesterol and apolipoprotein E.

Authors:  Raghda Lahdo; Laurence De La Fournière-Bessueille
Journal:  Biochem J       Date:  2004-09-15       Impact factor: 3.857

4.  Apolipoprotein E and cholesterol in aging and disease in the brain.

Authors:  Elena Posse de Chaves; Vasanthy Narayanaswami
Journal:  Future Lipidol       Date:  2008-10

Review 5.  Soluble apoE/Aβ complex: mechanism and therapeutic target for APOE4-induced AD risk.

Authors:  Leon M Tai; Shipra Mehra; Varsha Shete; Steve Estus; G William Rebeck; Guojun Bu; Mary Jo LaDu
Journal:  Mol Neurodegener       Date:  2014-01-04       Impact factor: 14.195

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.